(Q42727617)

5 November 2017

title

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684 (English)

1 reference

9 December 2024

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21838707

9 December 2024

6

Ruth H Palmer

1 reference

5 November 2017

7

Bengt Hallberg

1 reference

5 November 2017

2

Kristina Ruuth

1 reference

5 November 2017

4

Therese Eriksson

1 reference

5 November 2017

Christina Schönherr

1

1 reference

5 November 2017

Yasuo Yamazaki

3

1 reference

5 November 2017

James Christensen

5

1 reference

5 November 2017

Ruth H. Palmer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21838707

9 December 2024

language of work or name

English

0 references

publication date

1 December 2011

1 reference

5 November 2017

15 December 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21838707

9 December 2024

1 reference

5 November 2017

volume

440

1 reference

5 November 2017

issue

3

1 reference

5 November 2017

page(s)

405-413

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

5 November 2017

1 reference

Expression of the ALK tyrosine kinase gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Biological role of anaplastic lymphoma kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Anaplastic lymphoma kinase: signalling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

ALK, lung cancer, and personalized therapy: portent of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Crizotinib--latest champion in the cancer wars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Prediction of cancer driver mutations in protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101796

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

21 January 2018

5

1 reference

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

9 December 2024

29

1 reference

The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo

9 December 2024

32

1 reference

9 December 2024

Identifiers

DOI

10.1042/BJ20101796

1 reference

5 November 2017

1 reference